Amazing number of trials for Alzheimer's in

New Post Public Reply Private Reply Replies (1) Message Board

Dec 5, 2015 at 9:28 PM

Amazing number of trials for Alzheimer's in NYS,
Fletch

https://www.nia.nih.gov/alzheimers/clinical-t...y=New-York

Your Search for state of New-York Identified 33 Trial(s):

1. ABT-957 in Subjects with Mild to Moderate Alzheimer's Taking Acetylcholinesterase Inhibitors
Purpose: To evaluate the safety, tolerability, and pharmacokinetics of ABT-957 in people with mild to moderate Alzheimer's disease.

2. AC-1204 for Mild to Moderate Alzheimer's Disease
Purpose: To evaluate the effects of AC-1204 on cognition, activities of daily living, quality of life, pharmacokinetic measures, and safety in people with mild to moderate Alzheimer's disease.

3. Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Purpose: To build a clinical research consortium to test new treatments for people with frontotemporal lobar degeneration.

4. Aerobic & Cognitive Exercise Study (ACES)
Purpose: To clarify the benefits to brain health and thinking processes that result from different forms of exercise.

5. Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4)
Purpose: To test whether an anti-amyloid investigational drug, solanezumab, can slow memory and cognitive decline in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia.

6. AZD0530 in Mild Alzheimer's Disease (Connect Study)
Purpose: To determine the safety and efficacy of the experimental drug AZD0530 in older adults with mild Alzheimer's disease.

7. AZD3293 in Early Alzheimer's Disease (AMARANTH)
Purpose: To assess the efficacy and safety of AZD3293 as a possible treatment for early Alzheimer´s disease.

8. BAN2401 for Early Alzheimer's Disease
Purpose: To determine the effectiveness of the experimental drug BAN2401 as a possible treatment for people with mild cognitive impairment or mild Alzheimer's disease.

9. Benfotiamine in Alzheimer's Disease
Purpose: To determine whether treatment with benfotiamine, a dietary supplement, minimizes cognitive decline in older adults with amnestic mild cognitive impairment or mild Alzheimer's disease.

10. BI 409306 for Cognitive Impairment Due to Alzheimer's Disease
Purpose: To test the experimental drug BI 409306 in people with cognitive impairment due to Alzheimer's disease.

11. BI 409306 for Early-Stage Alzheimer's Disease
Purpose: To test the experimental drug BI 409306 in people with early Alzheimers disease.

12. Crenezumab for Mild to Moderate Alzheimer Disease
Purpose: To evaluate the safety and tolerability of crenezumab in older adults with mild to moderate Alzheimer's disease.

13. Dominantly Inherited Alzheimer Network (DIAN)
Purpose: To identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

14. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia (DIAN TU)
Purpose: To assess the safety, tolerability, and biomarker efficacy of gantenerumab and solanezumab in individuals who have a genetic mutation for autosomal-dominant Alzheimer's disease.

15. EMERGE: Aducanumab (BIIB037) for Early Alzheimer's Disease
Purpose: To evaluate treatment of early Alzheimer's disease with the experimental drug aducanumab (BIIB037).

16. ENGAGE: Aducanumab (BIIB037) for Early Alzheimer's Disease
Purpose: To evaluate treatment of early Alzheimer's disease with the experimental drug aducanumab (BIIB037).

17. Gantenerumab for Mild Alzheimer Disease
Purpose: To evaluate the efficacy and safety of the experimental drug gantenerumab as a possible treatment for people with mild Alzheimer disease.

18. Hispanic Caregiver Intervention Effectiveness Study
Purpose: To compare two dementia caregiver interventions to determine which is most effective for Hispanic caregivers in New York City.

19. Home-Delivered Intervention for Depressed, Cognitively Impaired Elders
Purpose: To test the efficacy of Problem Adaptation Therapy (PATH), a home-delivered psychosocial intervention for elders with major depression, memory problems, and disability.

20. Imaging of Cognition, Learning, and Memory in Aging
Purpose: To study how the brain functions when it performs explicit memory tasks and how this changes as a function of aging.

21. Longitudinal Evaluation of Familial Frontotemporal Dementia (LEFFTDS)
Purpose: To learn about thinking and behavior in families in which one or more relatives has a genetic mutation associated with frontotemporal dementia.

22. Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
Purpose: To determine whether positron emission tomography (PET) scanning can help distinguish patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than current clinical practices.

23. MK-7622 in People with Alzheimer's Disease Taking Donepezil
Purpose: To test the efficacy and safety of MK-7622 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.

24. MK-8931 for Amnestic Mild Cognitive Impairment (APECS)
Purpose: To assess MK-8931 as a possible treatment for amnestic mild cognitive impairment due to Alzheimer's disease.

25. NOBLE: T-817MA for Mild to Moderate Alzheimer's Disease
Purpose: To evaluate the efficacy of the experimental drug T-817MA as a potential treatment for people with mild to moderate Alzheimer's disease.

26. Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Older Adults
Purpose: To determine if a worsened sense of smell can identify older people who might benefit from treatment with the Alzheimer's drug donepezil.

27. PET Imaging with 18F-AV-1451
Purpose: To evaluate the characteristics of the brain imaging agent 18F-AV-1451 in cognitively healthy volunteers and in people with mild cognitive impairment or Alzheimer's disease.

28. Prediction of Mild Cognitive Impairment and Pioglitazone to Delay Its Onset (TOMMORROW)
Purpose: To develop a biomarker that predicts the risk of mild cognitive impairment due to Alzheimer's disease and to test the drug pioglitazone to delay the onset of MCI.

29. Riluzole for Mild Alzheimer's Disease
Purpose: To test the safety and effectiveness of the drug riluzole for treating mild Alzheimer's disease.

30. Sleep-Disordered Breathing and Alzheimer's Disease Prevention (SNAP)
Purpose: To examine the relationship between sleep-disordered breathing and Alzheimer's disease in cognitive normal older adults.

31. STARBEAM: Lu AE58054 in People with Mild to Moderate Alzheimer's Disease Taking Donepezil
Purpose: To test Lu AE58054 as an add-on therapy to donepezil in people with mild to moderate Alzheimer's disease.

32. STARSHINE: Lu AE58054 in People with Mild to Moderate Alzheimer's Disease Taking Donepezil
Purpose: To test the drug Lu AE58054 as an add-on therapy to donepezil for people with mild to moderate Alzheimer's disease.

33. Treatment of Psychosis and Agitation in Alzheimer's Disease
Purpose: To test lithium as a treatment for psychosis and agitation in older adults with Alzheimer's disease.

Return to AD Clinical Trials Search Results

Return to AD Clinical Trials Home

Anavex Life Sciences Corp. (AVXL) Stock Research Links

AVXL Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viedoc and Bioforum Unite: Clinical Data Innovation

Revamping Clinical Trials with Data Integration It doesn't take a Wall Street wizard to understand that in today's research game, having data is only half the battle—using it effectively is where the rubber meets the road. Enter Viedoc and Bioforum, two names that are well-acquainted with the grind of the clinical research world. These seasoned pros have joined forces,...

Service Pros Adds Windshield Repair to Lineup

Revving Up the Service Engine Alright, folks, buckle up because Service Pros Auto Glass, our local go-to for windshield replacements, is cranking up their game. They're stepping into the windshield repair arena across Florida and South Carolina, aiming to save you a buck and keep you safe behind the wheel. That's a double win if you ask me. A Closer Look at the Details...

CNOOC Limited's 2026 Surge: New Projects, New Heights

Production Peaks and New Discoveries Over in the bustling corridors of oil and gas, CNOOC Limited is making some strong waves. Why? Because they’ve hit historical peaks in production in the first three quarters of 2026. We’re talking about a net production of 593.7 million barrels of oil equivalent. That’s a 2.7% climb from last year. Seems like CNOOC is really...

Ex-Guard Pushes Cost-Saving Grille Guards as Deer Season Hits

Deer Season's Bumper Problem If you're driving a hefty pickup or van in the thick of deer season, forget looking at pretty autumn leaves. Instead, brace for the telltale thud—and the ensuing financial headache—that comes with a deer collision. Anyone who's tangled with such a mishap knows it's not just about the dent in your fender; it's about your wallet getting...

Huawei's New O&M Strategies: A Game-Changer?

Huawei's Latest O&M Revolution: What's on the Table? With Huawei dropping fresh O&M solutions at HUAWEI CONNECT 2026 in Shanghai, they're not just shaking things up—they're kicking the whole operation management game into hyperdrive using AI. They're zeroing in on the whole digital twin strategy, boasting some nifty pre-event, in-process, and post-event capabilities to...

Bambusa Therapeutics: IPO Priced At $16, Shares On Nasdaq

How Does Bambusa Therapeutics Stack Up? Well, here we go again in the biotech bonanza, folks. Bambusa Therapeutics is stepping onto the stage with their shiny new upsized IPO, offering a whopping 10,555,555 shares at sixteen bucks a pop. That's real money, coming in at $168,888,880 in gross proceeds if everything goes according to plan. Seems like a hefty sum, but in this...

Sobi Names Börje Ekholm as Chair Amid New Data

An Offbeat Choice for Chair? So, Sobi's gone and picked Börje Ekholm as the proposed Chair of their Board. Now, this might raise some eyebrows out there—Ekholm's no stranger to top roles, having steered the ship at Ericsson. The twist here is usually these Chair announcements hum along without much fanfare, but chuck in Ekholm and you get a bit of buzz—probably...

Birth Injury Lawsuit Secures $19.1M Award in Michigan

Legal Triumph for Sokolove's Birth Injury Case There are days when you see a win in the courtroom and think maybe, just maybe, justice ain't just a fairytale. Today, that thought knocks heavier with news rolling out of Michigan—an astronomical $19.1 million awarded to a family by a federal judge after a botched birth led to lifelong medical issues. You've got Sokolove...

ACCULOAD: Aiming for Safer, Easier Boat Loading

Getting a boat onto a trailer? It can turn into a circus act if you're not careful. Visibility's shot, conditions change faster than a stock ticker, and alignment's like threading a needle blindfolded. Out comes ACCULOAD, a novel idea created by some intrepid inventor down in Slocomb, Ala, aiming to solve what’s been a pain point for boaters worldwide. What's ACCULOAD...

Foxconn Shakes Up EV Scene with New Models Unveiled

Foxconn Boldly Claims New Ground in EV Market Foxconn's at it again, thumping its chest in the electric vehicle arena with three fresh rides that scream ambition. At the HHTD26 in Taipei, they rolled out the MODEL A+, MODEL K+, and MODEL K—vehicles that not only diversify their portfolio but target segments that rarely see such a jolt. Does it get your gears turning?...